MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pemetrexed (Alimta)

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Clinical Lung Cancer 2018 May 9 [Link] Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K

Comments Off on A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

BMC Cancer 2018 April [Link] Giger-Pabst, Demtröder, Falkenstein, Ouaissi, Götze, Rezniczek, Tempfer Abstract BACKGROUND: Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options. METHODS: We performed a retrospective cohort study of patients with recurrent MM undergoing Pressurized IntraPeritoneal/Thoracal Aerosol Chemotherapy (PIPAC/PITAC) with doxorubicin 1.5 mg/m2 and cisplatin 7.5 mg/m2. […]

Comments Off on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 Februrary [Link] Oehl K et. al. Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 February [Link] Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

Cancer Medicine 2018 February 26 [Epub ahead of print] [Link] Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC Abstract This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density, […]

Comments Off on Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

BMC Cancer 2018 February 17 [Link] de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA Abstract BACKGROUND: Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in the […]

Comments Off on A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Annals of Surgical Oncology 2018 February [Epub ahead of print] [Link] Alexander HR Jr., Li CY, Kennedy TJ Abstract PURPOSE: Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity […]

Comments Off on Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Anti-tumor immunotherapy in malignant pleural mesothelioma

Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date. […]

Comments Off on Anti-tumor immunotherapy in malignant pleural mesothelioma

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy

Frontiers in Pharmacology 2018 January 11 [Link] Oien DB, Garay T, Eckstein S, Chien J Abstract Reactive oxygen species (ROS) can promote or inhibit tumorigenesis. In mesothelioma, asbestos exposure to serous membranes induces ROS through iron content and chronic inflammation, and ROS promote cell survival signaling in mesothelioma. Moreover, a current chemotherapy regimen for mesothelioma […]

Comments Off on Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy

Systemic Treatment of Malignant Pleural Mesothelioma

Cancer & Chemotherapy 2017 December [Link] Nakano T Abstract Malignant pleural mesothelioma(MPM)is a highly aggressive tumor with a poor prognosis and an increasing incidence worldwide. The only standard first-line chemotherapy for patients with unresectable MPM is cisplatin(CDDP)plus peme- trexed(PEM)(CDDP/PEM), with a median overall survival of about 12months and a median progression-free survival(PFS) of less than […]

Comments Off on Systemic Treatment of Malignant Pleural Mesothelioma